Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03551249 · ClinicalTrials.gov registry record · NA
Assessment of Safety and Feasibility of ExAblate Blood-Brain Barrier (BBB) Disruption
A NA study of Glioblastoma and Glioma, sponsored by InSightec.
- Completed
- Registry status
- NA
- Development phase
- 20
- Enrollment target
- 4
- Study locations
NCT03551249 is a NA study of Glioblastoma and Glioma that has completed, run by InSightec. The registered enrollment target is 20 participants, below the 109-participant average among 199 other Glioblastoma trials with a reported enrollment target (82% lower). The trial reports 4 study locations across 4 states.
The verdict
NCT03551249, a NA study of Glioblastoma and Glioma, has completed, sponsored by InSightec.
- COMPLETED
- Registry status
- NA
- Development phase
- 20 participants
- Enrollment target
- 4
- Study locations
Study Summary
The purpose of this study is to evaluate the safety of the ExAblate Model 4000 Type 2 used as a tool to disrupt the BBB (blood brain barrier) in patients with high grade glioma undergoing standard of care therapy.
Conditions Studied
Interventions
- DEVICE Focused ultrasound (FUS)
Study Locations (4)
Maryland
- University of Maryland - Baltimore
Massachusetts
- Brigham and Women's Hospital - Boston
Virginia
- University of Virginia - Charlottesville
West Virginia
- West Virginia University - Morgantown
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2019-03-26 |
| Est. Completion | 2023-12-31 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03551249
The ClinicalTrials.gov registry entry for NCT03551249 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 109-participant average among 199 other Glioblastoma trials with a reported enrollment target (82% lower). The listed sponsor is InSightec, which has 38 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Glioblastoma appearing as the primary indexed condition, and to 1 intervention - of which Focused ultrasound (FUS) is the first listed.
NCT03551249 reports 4 study locations spanning 4 distinct geographic areas - top geographies include Maryland, Massachusetts, Virginia.
Frequently Asked Questions
What is clinical trial NCT03551249 about?
NCT03551249 is a clinical study titled "Assessment of Safety and Feasibility of ExAblate Blood-Brain Barrier (BBB) Disruption". The purpose of this study is to evaluate the safety of the ExAblate Model 4000 Type 2 used as a tool to disrupt the BBB (blood brain barrier) in patients with high grade glioma undergoing standard of care therapy.
What is the current status of trial NCT03551249?
This trial is currently completed. It is a NA study. The enrollment target is 20 participants. The study started on 2019-03-26. Estimated completion is 2023-12-31.
What conditions does trial NCT03551249 study?
This clinical trial studies the following conditions: Glioblastoma, Glioma.
What interventions are being tested in trial NCT03551249?
The interventions under investigation include: Focused ultrasound (FUS) (DEVICE).
Who is sponsoring clinical trial NCT03551249?
This trial is sponsored by InSightec, which has 38 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03551249 being conducted?
This trial has 4 study locations across Maryland, Massachusetts, Virginia, West Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glioblastoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Glioblastoma Remote Monitoring and Care - Research Protocol
RECRUITING · NA
-
Evaluation of the CONVIVO System
RECRUITING · NA
-
Adaptive Radiotherapy and MRIs Based on Patients With Newly Diagnosed High-Grade Glioma
RECRUITING · NA
-
LITT Followed by Hypofractionated RT for Newly Diagnosed Gliomas (GCC 20138)
RECRUITING · NA
-
Customized Neuro-Imaging Referenced Symptom Video for the Reduction of Patient and Caregiver Anxiety Around Radiation Treatment for Brain Tumors
RECRUITING · NA
-
Sonobiopsy for Noninvasive and Sensitive Detection of Glioblastoma
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.